SciSparc (SPRC) announced Monday the publication of a European patent application that its collaboration partner Clearmind Medicine (CMND) submitted with the European Patent Office for a binge behavior psychedelic combination treatment.
The companies are researching combination treatments that integrate psychedelic molecules with the N-acylethanolamines family, SciSparc said.
Shares of SciSparc soared 188% and Clearmind Medicine rose 4% in premarket activity Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.